BACKGROUND:alpha-tocopherol supplementation significantly reduced risk of prostate cancer in the Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC) Study. Sex hormones are thought to be involved in the etiology of prostate cancer. We examined whether long-term supplementation with alpha-tocopherol modified serum hormone levels. METHODS:Men who were cancer-free consumed > or = 90% of the study capsules, and who had both baseline and follow-up blood available, were eligible for the study. One hundred men who received alpha-tocopherol were matched on age, study center, and length of time between blood draws to 100 men who received aplacebo. Multivariate linear regression models which allowed for a separate intercept for each matched pair were used to evaluate the effect of alpha-tocopherol supplementation on follow-up hormone concentrations. RESULTS: Compared to men who received a placebo, we found significantly lower serum androstenedione (P = 0.04) and testosterone (P = 0.04) concentrations among men who received alpha-tocopherol, after controlling for baseline hormone level, follow-up serum cholesterol concentration, body mass index, smoking, and fasting time. Geometric mean (95% confidence interval; CI) androstenedione concentration among men who received alpha-tocopherol was 145 ng/dl (CI, 137-153) after adjusting for covariates, compared to 158 ng/dl (CI, 148-167) among men who received a placebo. Mean testosterone concentrations for men who received alpha-tocopherol and placebo were 539 (CI, 517-562) and 573 (CI, 549-598) ng/dl, respectively. CONCLUSIONS: These results suggest that long-term alpha-tocopherol supplementation decreases serum androgen concentrations, and could have been one of the factors contributing to the observed reduction in incidence and mortality of prostate cancer in the alpha-tocopherol treatment group of the ATBC Study. Copyright 2001 Wiley-Liss, Inc.
RCT Entities:
BACKGROUND:alpha-tocopherol supplementation significantly reduced risk of prostate cancer in the Alpha-TocopherolBeta-CaroteneCancer Prevention (ATBC) Study. Sex hormones are thought to be involved in the etiology of prostate cancer. We examined whether long-term supplementation with alpha-tocopherol modified serum hormone levels. METHODS:Men who were cancer-free consumed > or = 90% of the study capsules, and who had both baseline and follow-up blood available, were eligible for the study. One hundred men who received alpha-tocopherol were matched on age, study center, and length of time between blood draws to 100 men who received a placebo. Multivariate linear regression models which allowed for a separate intercept for each matched pair were used to evaluate the effect of alpha-tocopherol supplementation on follow-up hormone concentrations. RESULTS: Compared to men who received a placebo, we found significantly lower serum androstenedione (P = 0.04) and testosterone (P = 0.04) concentrations among men who received alpha-tocopherol, after controlling for baseline hormone level, follow-up serum cholesterol concentration, body mass index, smoking, and fasting time. Geometric mean (95% confidence interval; CI) androstenedione concentration among men who received alpha-tocopherol was 145 ng/dl (CI, 137-153) after adjusting for covariates, compared to 158 ng/dl (CI, 148-167) among men who received a placebo. Mean testosterone concentrations for men who received alpha-tocopherol and placebo were 539 (CI, 517-562) and 573 (CI, 549-598) ng/dl, respectively. CONCLUSIONS: These results suggest that long-term alpha-tocopherol supplementation decreases serum androgen concentrations, and could have been one of the factors contributing to the observed reduction in incidence and mortality of prostate cancer in the alpha-tocopherol treatment group of the ATBC Study. Copyright 2001 Wiley-Liss, Inc.
Authors: Sara Lindström; Jing Ma; David Altshuler; Edward Giovannucci; Elio Riboli; Demetrius Albanes; Naomi E Allen; Sonja I Berndt; Heiner Boeing; H Bas Bueno-de-Mesquita; Stephen J Chanock; Alison M Dunning; Heather Spencer Feigelson; J Michael Gaziano; Christopher A Haiman; Richard B Hayes; Brian E Henderson; David J Hunter; Rudolf Kaaks; Laurence N Kolonel; Loic Le Marchand; Carmen Martínez; Kim Overvad; Afshan Siddiq; Meir Stampfer; Pär Stattin; Daniel O Stram; Michael J Thun; Dimitrios Trichopoulos; Rosario Tumino; Jarmo Virtamo; Stephanie J Weinstein; Meredith Yeager; Peter Kraft; Matthew L Freedman Journal: J Clin Endocrinol Metab Date: 2010-06-09 Impact factor: 5.958
Authors: Alison M Mondul; Sabine Rohrmann; Andy Menke; Manning Feinleib; William G Nelson; Elizabeth A Platz; Demetrius Albanes Journal: Cancer Causes Control Date: 2011-03-20 Impact factor: 2.506
Authors: Jarmo Virtamo; Phil R Taylor; Jukka Kontto; Satu Männistö; Meri Utriainen; Stephanie J Weinstein; Jussi Huttunen; Demetrius Albanes Journal: Int J Cancer Date: 2013-12-12 Impact factor: 7.396
Authors: Enitome E Bafor; Adaeze P Uchendu; Omorede E Osayande; Osemelomen Omoruyi; Uyi G Omogiade; Evuarherhere E Panama; Olusola O Elekofehinti; Ebube L Oragwuncha; Asanat Momodu Journal: Reprod Sci Date: 2020-07-28 Impact factor: 3.060
Authors: Demetrius Albanes; Cathee Till; Eric A Klein; Phyllis J Goodman; Alison M Mondul; Stephanie J Weinstein; Philip R Taylor; Howard L Parnes; J Michael Gaziano; Xiaoling Song; Neil E Fleshner; Powel H Brown; Frank L Meyskens; Ian M Thompson Journal: Cancer Prev Res (Phila) Date: 2014-06-24
Authors: Joanne L Watters; Mitchell H Gail; Stephanie J Weinstein; Jarmo Virtamo; Demetrius Albanes Journal: Cancer Res Date: 2009-04-21 Impact factor: 12.701
Authors: Sunni L Mumford; Richard W Browne; Karen C Schliep; Jonathan Schmelzer; Torie C Plowden; Kara A Michels; Lindsey A Sjaarda; Shvetha M Zarek; Neil J Perkins; Lynne C Messer; Rose G Radin; Jean Wactawski-Wende; Enrique F Schisterman Journal: J Nutr Date: 2015-11-18 Impact factor: 4.798
Authors: Goran Bjelakovic; Dimitrinka Nikolova; Lise Lotte Gluud; Rosa G Simonetti; Christian Gluud Journal: Cochrane Database Syst Rev Date: 2012-03-14